PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2024. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a perso ...

文章核心观点 - Zacks Premium是一个可以帮助投资者更好地利用股票市场、更有信心投资的研究服务 [1] - Zacks Style Scores是一组辅助指标,可以帮助投资者选择有更好机会战胜市场的股票 [2][3][4] - Zacks Style Scores与Zacks Rank结合使用,可以帮助投资者构建更成功的投资组合 [5][6] 行业分析 - Amicus Therapeutics是一家专注于罕见代谢性疾病的生物技术公司,其主要产品Galafold是首个也是唯一一个获批的口服精准药物,用于治疗法布里病 [7] - Amicus Therapeutics的股票评级为2(买入),VGM评分为A,动量评分为A,表现良好 [7][8] - 两名分析师在过去60天内上调了公司2024财年的盈利预测,预测每股收益为0.22美元,平均盈利惊喜率为24% [7]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

文章核心观点 - 分析师对Amicus Therapeutics公司的盈利前景持乐观态度,预计其股价将继续上涨 [1][5] - 公司的盈利预测不断上调,反映了分析师对其业绩前景的乐观预期 [1][2] - 公司目前被评为Zacks Rank 1(强烈买入),这是一个可靠的股票评级工具,能帮助投资者做出正确的投资决策 [5] 当前季度盈利预测修订 - 当前季度每股收益预测为0.08美元,较去年同期增长214.29% [3] - 过去30天内,公司当前季度盈利预测上调63.64%,反映了分析师的乐观态度 [3] 全年盈利预测修订 - 全年每股收益预测为0.22美元,较去年同期增长143.14% [4] - 过去一个月内,公司全年盈利预测上调20.45%,反映了分析师的乐观态度 [4] 总结 - 公司的盈利预测不断上调,反映了分析师对其业绩前景的乐观预期,这也推动了公司股价的上涨 [1][2][6] - 公司目前被评为Zacks Rank 1(强烈买入),这是一个可靠的股票评级工具,能帮助投资者做出正确的投资决策 [5]

文章核心观点 - Amicus Therapeutics与Teva Pharmaceuticals签署许可协议,解决了之前的专利诉讼[1][2] - Amicus公司的主要上市药物Galafold是治疗法布里病的首个和唯一获批的口服药物[1] - Galafold销售持续增长,公司提高了2024年的收入指引[4] - Amicus还有一款治疗晚发型庞贝病的两联疗法Pombiliti + Opfolda获批上市,为公司带来新的收入来源[5][6] 根据目录分别总结 Galafold销售情况 - Galafold自上市以来销售持续增长,2024年前6个月销售额达2.102亿美元,同比增长17%[4] - Galafold在美国、欧盟、英国和日本等多个国家获批上市[4] - 由于全球需求持续增长,Amicus公司提高了Galafold 2024年的收入指引,预计增长14-18%[4] - Galafold在美国拥有强大的知识产权保护,可提供至2038年的专利保护[4] Pompe病药物Pombiliti + Opfolda - 2023年9月,Pombiliti + Opfolda获得FDA批准,用于治疗成人晚发型庞贝病[5] - 该两联疗法也获得欧盟及英国的批准[5] - 该药物上市后势头良好,商业化患者数量持续增加[5] - Pombiliti + Opfolda的获批及上市缓解了Galafold独自承担Amicus公司收入的压力[6]

Amicus Therapeutics (FOLD) shares ended the last trading session 14% higher at $11.97. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 3.8% loss over the past four weeks. The sudden rise in the stock price was observed after Amicus announced signing a licensing agreement with Teva Pharmaceuticals which resolves the patent lawsuit filed earlier by FOLD. The litigation arose after Teva submitted an abbreviated new dr ...

文章核心观点 - 公司与Teva Pharmaceuticals达成许可协议,允许Teva在2037年1月30日之后在美国上市其GALAFOLD®仿制药[1][2] - 双方将终止所有关于GALAFOLD®专利的诉讼,但对Aurobindo的诉讼将继续进行,Lupin的诉讼暂时中止[2] - 公司将与美国联邦贸易委员会和司法部提交保密许可协议以供审查[2] 公司概况 - 公司是一家专注于罕见疾病领域的生物技术公司,致力于开发和提供创新的高质量药物[3] - 公司拥有专注于患者的承诺,致力于推进和扩大一系列一流或最佳的罕见疾病药物管线[3] 风险提示 - 公司面临来自仿制药制造商的竞争,这可能源于GALAFOLD®相关的"第四段"诉讼和其他专利诉讼的不利结果[4] - 许可协议的审查结果存在不确定性[4] - 美国FDA可能会大幅提前批准Teva的ANDA申请[4]

PRINCETON, N.J., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that three posters highlighting its development program for Pompe disease will be included at the 29th Annual Congress of the World Muscle Society being held October 8-12, 2024 in Prague, Czechia. Poster Session: Pompe Disease Abstract Title: Cipaglucosidase alfa + miglustat in late-onset Pompe disease: two non-ambulatory patients switching from high-dose, high-frequency alglucosidase alfa (Poster #657P) P ...

文章核心观点 - 公司股价长期陷入交易区间,主要原因是缺乏普通生物科技投资者和交易者的兴趣 [1] - 公司领导了一个名为"增长股论坛"的投资组合,包括定期更新的15-20只股票组合、预计在当前日历年表现良好的10只股票清单、短期和中期交易想法,以及社区对话和问答 [1] 行业和公司总结 - 公司是一家生物科技公司,股票代码为FOLD [1] - 公司长期股价表现平淡,缺乏普通投资者和交易者的兴趣 [1] - 公司领导了一个名为"增长股论坛"的投资组合,提供定期更新的股票组合、预计表现良好的股票清单、交易想法,以及社区互动 [1]

PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September. Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY, on Thursday, September 5, 2024, at 10:00 a.m. ET Cantor Global Healthcare Conference 2024 in New York, NY on Tuesday, September 17, 2024, at 1:55 p.m. ET A live audio webcast of each presentation can also be accessed via the ...